Literature DB >> 16965579

Optimal prewarming conditions for Rh antibody testing.

Teruo Endoh1, Daisuke Kobayashi, Naoki Tsuji, Hiromi Tanabe, Saori Koshida, Atsuhito Yagihashi, Naoki Watanabe.   

Abstract

BACKGROUND: Although prewarming (PW) can reduce the confounding agglutination of cold-reactive antibodies when testing for warm-reactive antibodies, PW also can adversely affect the detection of warm-reactive antibodies. This study was conducted to determine PW conditions that optimized Rh antibody detection. STUDY DESIGN AND METHODS: In 38 plasma samples with Rh system antibodies detected by any of four methods, and in 8 other samples with cold-reactive antibodies, reactivity was assessed by titer and score.
RESULTS: PW to 37 degrees C often reduced reaction scores by all methods especially the low-ionic-strength saline indirect antiglobulin test and bromelin methods. In analyses warming red blood cell (RBC) suspensions or plasma, the reaction scores were decreased only when the RBC suspension was warmed, suggesting that RBC PW decreased Rh antibody reactivity. The warming period ranging from 5 to 30 minutes all decreased Rh system reaction scores, an effect persisting up to 120 minutes. At lower temperatures (27, 30, and 33 degrees C), numbers of samples showing decreased reaction score for Rh system antibodies decreased in a temperature-dependent manner. Testing at 27 degrees C also permitted some agglutination involving cold-reactive antibodies, whereas higher temperatures successfully suppressed their agglutination.
CONCLUSION: PW at 30 degrees C minimizes problems in accurately detecting Rh system antibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965579     DOI: 10.1111/j.1537-2995.2006.00942.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  1 in total

1.  Methods for quantitative detection of antibody-induced complement activation on red blood cells.

Authors:  Elisabeth M Meulenbroek; Diana Wouters; Sacha Zeerleder
Journal:  J Vis Exp       Date:  2014-01-29       Impact factor: 1.355

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.